MCID: EWN002
MIFTS: 49

Ewing's Family of Tumors

Categories: Rare diseases, Genetic diseases, Bone diseases, Neuronal diseases

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 49
Neuroectodermal Tumor, Primitive 69
Primitive Neuroectodermal Tumor 49
Ewing Family of Tumors 49
Ewing’s Tumor of Bone 49
Extraosseous Ewing’s 49
Askin’s Tumor 49

Classifications:



Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to ewing sarcoma and sarcoma. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Vincristine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include bone, nk cells and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 30.7 CDKN2A CSF3 EWSR1 FLI1 KIT KITLG
2 sarcoma 30.7 EWSR1 FLI1 KIT RB1
3 extraosseous ewing's sarcoma 12.6
4 askin's tumor 12.5
5 supratentorial primitive neuroectodermal tumor 12.5
6 cerebral primitive neuroectodermal tumor 12.4
7 intracranial primitive neuroectodermal tumor 12.4
8 extraosseous ewings sarcoma-primitive neuroepithelial tumor 11.6
9 kaposiform hemangioendothelioma 10.5 FLI1 MTOR
10 indolent systemic mastocytosis 10.4 KIT KITLG
11 cutaneous mastocytosis 10.4 KIT KITLG
12 transient erythroblastopenia of childhood 10.4 EPO KITLG
13 kidney fibrosarcoma 10.4 EPO EWSR1
14 aggressive systemic mastocytosis 10.4 KIT KITLG
15 uterine body mixed cancer 10.3 ERBB2 KIT
16 toxic optic neuropathy 10.3 EPO ERBB2
17 breast adenoid cystic carcinoma 10.3 ERBB2 KIT
18 urticaria pigmentosa 10.3 KIT KITLG
19 vulvar seborrheic keratosis 10.3 CDKN2A MTOR
20 acquired polycythemia 10.3 EPO EPOR
21 myxoid chondrosarcoma 10.2 CDKN2B EWSR1
22 cutaneous solitary mastocytoma 10.2 KIT KITLG
23 malignant mesenchymoma 10.2 CDK4 EWSR1 KIT
24 breast papillomatosis 10.2 CDKN2A ERBB2
25 erythrocytosis, familial, 2 10.2 EPO EPOR
26 connective tissue cancer 10.2 CDK4 EWSR1 KIT
27 histiocytoma 10.2 CDK4 EWSR1 KIT
28 fallopian tube endometrioid adenocarcinoma 10.2 CDKN2A ERBB2
29 rhabdomyosarcoma 10.2
30 infiltrating angiolipoma 10.2 CDK4 CDKN2A
31 vulval paget's disease 10.2 CDKN2A ERBB2
32 desmoplastic small round cell tumor 10.2 CSF3 EWSR1 FLI1
33 neonatal anemia 10.2 EPO EPOR
34 vulva adenocarcinoma 10.2 CDKN2A ERBB2
35 adenoid basal cell carcinoma 10.1 CDKN2A KIT
36 primary polycythemia 10.1 EPO EPOR
37 spindle cell liposarcoma 10.1 CDK4 KIT
38 skin sarcoma 10.1 CDK4 CDKN2B EWSR1
39 acute erythroid leukemia 10.1 EPO EPOR FLI1
40 doxorubicin induced cardiomyopathy 10.1 CSF3 EPOR
41 acral lentiginous melanoma 10.1 CDKN2A KIT
42 polycythemia 10.1 EPO EPOR KITLG
43 luminal breast carcinoma 10.1 ERBB2 MTOR
44 oral leukoplakia 10.1 CDKN2A ERBB2
45 plasmablastic lymphoma 10.1 CDKN2A MTOR
46 ischemic fasciitis 10.1 CDK4 CDKN2A
47 tenosynovial giant cell tumor 10.0 CDKN2A CDKN2B
48 spindle cell lipoma 10.0 CDK4 RB1
49 thyroid lymphoma 10.0 CDKN2A CDKN2B
50 neurofibroma 10.0 CDKN2A KIT KITLG

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.16 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.16 MTOR EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.16 MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.16 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.16 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.16 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.16 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.16 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.16 EWSR1 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.16 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.16 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.16 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.16 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.16 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.16 CDK4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.16 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.16 CDK4 KIT MTOR EWSR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.16 CDK4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.16 EWSR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.16 MTOR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.16 EWSR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.16 MTOR KIT CDK4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.16 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.16 KIT EWSR1
25 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
26 Decreased substrate adherent cell growth GR00193-A-2 9.7 CDK4 KIT MTOR
27 Decreased substrate adherent cell growth GR00193-A-3 9.7 CDK4
28 Decreased substrate adherent cell growth GR00193-A-4 9.7 CDK4 KIT
29 Increased transferrin (TF) endocytosis GR00363-A 9.32 CDKN2A CDKN2B EPO KITLG EPOR MTOR

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

43 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
2 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A KIT FLI1 KITLG RB1
3 hematopoietic system MP:0005397 10.35 CDKN2B CDKN2A CSF3 EPO CDK4 FLI1
4 immune system MP:0005387 10.33 CDKN2B CDKN2A CSF3 CDK4 FLI1 KITLG
5 homeostasis/metabolism MP:0005376 10.3 CDKN2A CDK4 CDKN2B KITLG KIT RB1
6 embryo MP:0005380 10.29 CDKN2A EPO CDK4 FLI1 KITLG KIT
7 endocrine/exocrine gland MP:0005379 10.28 CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
8 growth/size/body region MP:0005378 10.27 CDKN2A CDK4 FAS KIT FLI1 KITLG
9 mortality/aging MP:0010768 10.27 CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
10 integument MP:0010771 10.24 CDKN2B CDKN2A CSF3 CDK4 KITLG KIT
11 liver/biliary system MP:0005370 10.16 CDK4 CDKN2A FLI1 KITLG KIT RB1
12 digestive/alimentary MP:0005381 10.14 CDKN2A CDK4 KITLG FAS KIT RB1
13 nervous system MP:0003631 10.13 CDK4 CDKN2A KITLG KIT FLI1 RB1
14 neoplasm MP:0002006 10.11 CDKN2B CDKN2A CDK4 FLI1 KITLG KIT
15 muscle MP:0005369 10.08 CDK4 CDKN2A KIT FLI1 RB1 MTOR
16 limbs/digits/tail MP:0005371 10 FAS KIT KITLG RB1 EPO ERBB2
17 normal MP:0002873 9.97 CDK4 FAS KIT RB1 MTOR ERBB2
18 no phenotypic analysis MP:0003012 9.88 CDKN2A CDKN2B KIT RB1 MTOR EPOR
19 pigmentation MP:0001186 9.8 CDK4 CDKN2A KIT KITLG RB1 FAS
20 renal/urinary system MP:0005367 9.8 CDK4 CDKN2B CSF3 KIT RB1 MTOR
21 reproductive system MP:0005389 9.76 CDKN2A CDK4 CDKN2B KITLG FAS KIT
22 respiratory system MP:0005388 9.56 CDKN2A KIT RB1 MTOR EPO EPOR
23 skeleton MP:0005390 9.23 CDKN2A FAS KIT KITLG RB1 MTOR

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 920)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
6
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
8
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
9
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 6400441 383414
11
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
13
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
14
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
15
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
16
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
17
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
18 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
19
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
21
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
22
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
23
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
24
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53643-48-4, 59917-39-4 40839
25
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
27
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
28
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
29
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
30
Diazoxide Approved Phase 4,Phase 3,Phase 2 364-98-7 3019
31
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
32
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
33
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
34
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
35 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
36
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
37
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
38 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
39
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
40
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
41
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
42
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
43
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 149647-78-9 5311
44
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
45
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 44462760 44516822
46
Palbociclib Approved, Investigational Phase 4,Phase 2,Phase 1 571190-30-2 5330286 11431660 5005498
47
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
48
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
49
Zinc Approved, Investigational Phase 4,Phase 1,Not Applicable 7440-66-6 32051 23994
50
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 1 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 4855)

# Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
4 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
5 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4 RAD001
6 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
7 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
8 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
9 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
10 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
11 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
12 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
13 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
14 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
15 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
16 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
17 Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Recruiting NCT03017872 Phase 4 N(t)RTIs;Dolutegravir;Darunavir;Ritonavir
18 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
19 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
20 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
21 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
22 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
23 Seizure Treatment in Glioma Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
24 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
25 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
26 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
27 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
28 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
29 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
30 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
31 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
32 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
33 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
34 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
35 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
36 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
37 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
38 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
39 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
40 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
41 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
42 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
43 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
44 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
45 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
46 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
47 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
48 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
49 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
50 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

38
Bone, Nk Cells, T Cells, Testes, Lung, Kidney, Brain

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show all 13)
# Title Authors Year
1
High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. ( 21342043 )
2011
2
Ewing's family of tumors of the sinonasal tract and maxillary bone. ( 21107767 )
2011
3
Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. ( 17695539 )
2007
4
Single center experience of treatment of Ewing's family of tumors in Japan. ( 16437346 )
2006
5
Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). ( 17163151 )
2006
6
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. ( 15781877 )
2005
7
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. ( 15930281 )
2005
8
Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. ( 15125709 )
2004
9
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. ( 12972518 )
2003
10
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. ( 12885818 )
2003
11
Ewing's family of tumors involving structures related to the central nervous system: a review. ( 10742406 )
2000
12
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. ( 10458232 )
1999
13
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. ( 9850016 )
1998

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2
Show member pathways
13.55 CSF3 EPO EPOR ERBB2 FAS KIT
3
Show member pathways
13.47 CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4
Show member pathways
13.31 CSF3 EPOR ERBB2 FAS KIT KITLG
5
Show member pathways
13.05 CDK4 CDKN2A CDKN2B EPO MTOR RB1
6
Show member pathways
12.9 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
7
Show member pathways
12.53 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8
Show member pathways
12.5 CDK4 FAS MTOR RB1
9
Show member pathways
12.5 CDK4 CDKN2A CDKN2B RB1
10 12.49 FAS FLI1 KIT KITLG
11
Show member pathways
12.48 CDK4 CDKN2A ERBB2 MTOR RB1
12
Show member pathways
12.43 CDK4 CSF3 EPO EPOR FAS KIT
13 12.37 CDK4 CDKN2A CDKN2B RB1
14
Show member pathways
12.3 CDK4 CDKN2A FAS RB1
15
Show member pathways
12.29 CDK4 CDKN2A CDKN2B RB1
16
Show member pathways
12.28 CSF3 EPO EPOR MTOR
17 12.25 CDK4 CDKN2A CDKN2B KITLG RB1
18 12.22 CDK4 CDKN2A CDKN2B RB1
19
Show member pathways
12.15 CDK4 ERBB2 MTOR RB1
20
Show member pathways
12.13 CDK4 CDKN2A CDKN2B RB1
21 12.09 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
22
Show member pathways
12.08 EPO EPOR KIT KITLG
23 12.06 CDK4 MTOR RB1
24 12.04 ERBB2 KIT KITLG
25 12.03 CDK4 CDKN2A CDKN2B MTOR RB1
26
Show member pathways
11.99 CDK4 CDKN2A ERBB2 MTOR RB1
27 11.97 CDK4 CDKN2A FAS MTOR
28 11.89 CSF3 EPO KIT KITLG
29 11.88 CDKN2A MTOR RB1
30 11.86 CDK4 CDKN2A MTOR RB1
31 11.85 EPO ERBB2 MTOR
32 11.81 CDK4 CDKN2B RB1
33 11.77 EPO EPOR MTOR
34 11.69 CDKN2A ERBB2 FAS
35 11.66 CDK4 MTOR RB1
36 11.62 ERBB2 KIT MTOR
37 11.62 CDK4 CDKN2A ERBB2 RB1
38 11.54 CSF3 EPO EPOR KIT KITLG
39 11.49 CDKN2A FAS RB1
40 11.45 EPO KIT KITLG
41 11.41 CDK4 CDKN2B RB1
42 11.35 CSF3 EPO FLI1 KITLG
43 11.22 CDK4 CDKN2A CDKN2B
44 11.04 CDKN2A RB1
45 10.96 CSF3 EPOR ERBB2 KIT KITLG
46 10.89 KIT KITLG

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 CDK4 EPO EPOR ERBB2 FAS KIT
2 positive regulation of gene expression GO:0010628 9.89 CDKN2A ERBB2 KIT MTOR
3 regulation of transcription by RNA polymerase II GO:0006357 9.89 EPO ERBB2 FLI1 KIT RB1
4 positive regulation of cell proliferation GO:0008284 9.88 CDK4 CSF3 EPO KIT KITLG
5 cytokine-mediated signaling pathway GO:0019221 9.79 CSF3 EPOR KIT
6 phosphatidylinositol phosphorylation GO:0046854 9.73 ERBB2 KIT KITLG
7 phosphorylation GO:0016310 9.73 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8 G1/S transition of mitotic cell cycle GO:0000082 9.72 CDK4 CDKN2A RB1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 CSF3 KITLG MTOR
10 positive regulation of translation GO:0045727 9.63 CDK4 ERBB2 MTOR
11 negative regulation of phosphorylation GO:0042326 9.61 CDKN2A CDKN2B
12 positive regulation of Ras protein signal transduction GO:0046579 9.6 EPO KITLG
13 response to hyperoxia GO:0055093 9.58 CDK4 EPO
14 megakaryocyte development GO:0035855 9.58 FLI1 KIT
15 positive regulation of MAP kinase activity GO:0043406 9.58 ERBB2 KIT KITLG
16 embryonic hemopoiesis GO:0035162 9.57 KIT KITLG
17 positive regulation of transcription by RNA polymerase III GO:0045945 9.54 ERBB2 MTOR
18 somatic stem cell division GO:0048103 9.51 CDKN2A KIT
19 cell cycle arrest GO:0007050 9.46 CDKN2A CDKN2B MTOR RB1
20 ectopic germ cell programmed cell death GO:0035234 9.43 KIT KITLG
21 positive regulation of protein kinase B signaling GO:0051897 9.35 CSF3 ERBB2 KIT KITLG MTOR
22 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
23 erythropoietin-mediated signaling pathway GO:0038162 8.8 EPO EPOR KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.73 CDK4 ERBB2 KIT MTOR
2 identical protein binding GO:0042802 9.73 EPOR ERBB2 EWSR1 FAS MTOR RB1
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 ERBB2 KIT KITLG
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN2A CDKN2B
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 ERBB2 KIT
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT KITLG
7 kinase activity GO:0016301 9.1 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8 protein binding GO:0005515 10.22 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....